Buscar
Pharming Group NV
PHARAñadir a la lista de seguimiento
13.770USD
+0.050+0.36%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
0.00Cap. mercado
--P/E TTM
Más Datos de Pharming Group NV Compañía
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Información de Pharming Group NV
Símbolo de cotizaciónPHAR
Nombre de la empresaPharming Group NV
Fecha de salida a bolsaJul 02, 1998
Director ejecutivoChouraqui (Fabrice)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscal- -
DirecciónDarwinweg 24
CiudadLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 CR
Teléfono31715247400
Sitio Webhttps://www.pharming.com/
Símbolo de cotizaciónPHAR
Fecha de salida a bolsaJul 02, 1998
Director ejecutivoChouraqui (Fabrice)
Ejecutivos de Pharming Group NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Jabine Van Der Meijs
Ms. Jabine Van Der Meijs
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Steven Baert
Mr. Steven Baert
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ruud Van Outersterp
Mr. Ruud Van Outersterp
Chief Ethics and Compliance Officer
Chief Ethics and Compliance Officer
--
--
Dr. Richard Peters, M.D., Ph.D.
Dr. Richard Peters, M.D., Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Stephen (Steve) Toor
Mr. Stephen (Steve) Toor
Chief Commercial Officer
Chief Commercial Officer
--
--
Mrs. Mireille Sanders
Mrs. Mireille Sanders
Chief Operations Officer
Chief Operations Officer
--
--
Ms. Barbara Yanni
Ms. Barbara Yanni
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mark J. Pykett, M.D., Ph.D.
Dr. Mark J. Pykett, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Anurag Relan, M.D.
Dr. Anurag Relan, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Leonard Kruimer, CPA
Mr. Leonard Kruimer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Pharming Group NV?
Los cinco principales accionistas de Pharming Group NV son: Mr. Stephen (Steve) Toor
¿Cuántas instituciones poseen acciones de Pharming Group NV (PHAR)?
A fecha de 2026Q1, 22 instituciones poseen acciones de Pharming Group NV, con un valor de mercado combinado de aproximadamente 135.73K, lo que representa el 0.19% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 61813.00.